Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors.

Farrell PJ, Zopf CJ, Huang HJ, Balakrishna D, Holub C, Bilakovics J, Fanjul A, Matuszkiewicz J, Plonowski A, Rolzin P, Banerjee U, Ermolieff J, Cheruvallath ZS, McBride C, Bartkowski D, Mazur C, Pachori A, Larson CJ.

J Pharmacol Exp Ther. 2019 Nov;371(2):299-308. doi: 10.1124/jpet.119.259028. Epub 2019 Sep 19.

PMID:
31537613
2.

Increased association between Epstein-Barr virus EBNA2 from type 2 strains and the transcriptional repressor BS69 restricts EBNA2 activity.

Ponnusamy R, Khatri R, Correia PB, Wood CD, Mancini EJ, Farrell PJ, West MJ.

PLoS Pathog. 2019 Jul 8;15(7):e1007458. doi: 10.1371/journal.ppat.1007458. eCollection 2019 Jul.

3.

MetAP2 inhibition increases energy expenditure through direct action on brown adipocytes.

Huang HJ, Holub C, Rolzin P, Bilakovics J, Fanjul A, Satomi Y, Plonowski A, Larson CJ, Farrell PJ.

J Biol Chem. 2019 Jun 14;294(24):9567-9575. doi: 10.1074/jbc.RA118.007302. Epub 2019 May 2.

PMID:
31048375
4.

Towards a multi-level and a multi-disciplinary approach to DNA oncovirus virulence.

Alizon S, Bravo IG, Farrell PJ, Roberts S.

Philos Trans R Soc Lond B Biol Sci. 2019 May 27;374(1773):20190041. doi: 10.1098/rstb.2019.0041.

5.

Essential role of inverted repeat in Epstein-Barr virus IR-1 in B cell transformation; geographical variation of the viral genome.

Bridges R, Correia S, Wegner F, Venturini C, Palser A, White RE, Kellam P, Breuer J, Farrell PJ.

Philos Trans R Soc Lond B Biol Sci. 2019 May 27;374(1773):20180299. doi: 10.1098/rstb.2018.0299.

6.

Conditional validation sampling for consistent risk estimation with binary outcome data subject to misclassification.

Gravel CA, Farrell PJ, Krewski D.

Pharmacoepidemiol Drug Saf. 2019 Feb;28(2):227-233. doi: 10.1002/pds.4701.

PMID:
30746841
7.

Requirement for PRC1 subunit BMI1 in host gene activation by Epstein-Barr virus protein EBNA3C.

Paschos K, Bazot Q, Lees J, Farrell PJ, Allday MJ.

Nucleic Acids Res. 2019 Apr 8;47(6):2807-2821. doi: 10.1093/nar/gky1323.

8.

Epstein-Barr Virus and Cancer.

Farrell PJ.

Annu Rev Pathol. 2019 Jan 24;14:29-53. doi: 10.1146/annurev-pathmechdis-012418-013023. Epub 2018 Aug 20.

PMID:
30125149
9.

Sequence Variation of Epstein-Barr Virus: Viral Types, Geography, Codon Usage, and Diseases.

Correia S, Bridges R, Wegner F, Venturini C, Palser A, Middeldorp JM, Cohen JI, Lorenzetti MA, Bassano I, White RE, Kellam P, Breuer J, Farrell PJ.

J Virol. 2018 Oct 29;92(22). pii: e01132-18. doi: 10.1128/JVI.01132-18. Print 2018 Nov 15.

10.

A validation sampling approach for consistent estimation of adverse drug reaction risk with misclassified right-censored survival data.

Gravel CA, Dewanji A, Farrell PJ, Krewski D.

Stat Med. 2018 Nov 30;37(27):3887-3903. doi: 10.1002/sim.7854. Epub 2018 Aug 6.

PMID:
30084171
11.

A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection.

Bristol JA, Djavadian R, Albright ER, Coleman CB, Ohashi M, Hayes M, Romero-Masters JC, Barlow EA, Farrell PJ, Rochford R, Kalejta RF, Johannsen EC, Kenney SC.

PLoS Pathog. 2018 Jul 27;14(7):e1007179. doi: 10.1371/journal.ppat.1007179. eCollection 2018 Jul.

12.

The Cooperative Functions of the EBNA3 Proteins Are Central to EBV Persistence and Latency.

Styles CT, Paschos K, White RE, Farrell PJ.

Pathogens. 2018 Mar 17;7(1). pii: E31. doi: 10.3390/pathogens7010031. Review.

13.

Natural Variation of Epstein-Barr Virus Genes, Proteins, and Primary MicroRNA.

Correia S, Palser A, Elgueta Karstegl C, Middeldorp JM, Ramayanti O, Cohen JI, Hildesheim A, Fellner MD, Wiels J, White RE, Kellam P, Farrell PJ.

J Virol. 2017 Jul 12;91(15). pii: e00375-17. doi: 10.1128/JVI.00375-17. Print 2017 Aug 1.

14.

Molluscum Contagiosum Virus Protein MC005 Inhibits NF-κB Activation by Targeting NEMO-Regulated IκB Kinase Activation.

Brady G, Haas DA, Farrell PJ, Pichlmair A, Bowie AG.

J Virol. 2017 Jul 12;91(15). pii: e00545-17. doi: 10.1128/JVI.00545-17. Print 2017 Aug 1.

15.

MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody.

Farrell PJ, Matuszkiewicz J, Balakrishna D, Pandya S, Hixon MS, Kamran R, Chu S, Lawson JD, Okada K, Hori A, Mizutani A, Iwata H, de Jong R, Hibner B, Vincent P.

Mol Cancer Ther. 2017 Jul;16(7):1269-1278. doi: 10.1158/1535-7163.MCT-16-0771. Epub 2017 Mar 24.

16.

Roles of RUNX in B Cell Immortalisation.

West MJ, Farrell PJ.

Adv Exp Med Biol. 2017;962:283-298. doi: 10.1007/978-981-10-3233-2_18. Review.

17.

Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).

Lam B, Arikawa Y, Cramlett J, Dong Q, de Jong R, Feher V, Grimshaw CE, Farrell PJ, Hoffman ID, Jennings A, Jones B, Matuszkiewicz J, Miura J, Miyake H, Natala SR, Shi L, Takahashi M, Taylor E, Wyrick C, Yano J, Zalevsky J, Nie Z.

Bioorg Med Chem Lett. 2016 Dec 15;26(24):5947-5950. doi: 10.1016/j.bmcl.2016.10.087. Epub 2016 Nov 2.

PMID:
27839918
18.

Modeling U-shaped dose-response curves for manganese using categorical regression.

Milton B, Krewski D, Mattison DR, Karyakina NA, Ramoju S, Shilnikova N, Birkett N, Farrell PJ, McGough D.

Neurotoxicology. 2017 Jan;58:217-225. doi: 10.1016/j.neuro.2016.10.001. Epub 2016 Oct 5. Review.

PMID:
27720796
19.

Modeling U-Shaped Exposure-Response Relationships for Agents that Demonstrate Toxicity Due to Both Excess and Deficiency.

Milton B, Farrell PJ, Birkett N, Krewski D.

Risk Anal. 2017 Feb;37(2):265-279. doi: 10.1111/risa.12603. Epub 2016 Apr 4.

PMID:
27043736
20.

RUNX super-enhancer control through the Notch pathway by Epstein-Barr virus transcription factors regulates B cell growth.

Gunnell A, Webb HM, Wood CD, McClellan MJ, Wichaidit B, Kempkes B, Jenner RG, Osborne C, Farrell PJ, West MJ.

Nucleic Acids Res. 2016 Jun 2;44(10):4636-50. doi: 10.1093/nar/gkw085. Epub 2016 Feb 15.

21.

Epstein-Barr Virus Strain Variation.

Farrell PJ.

Curr Top Microbiol Immunol. 2015;390(Pt 1):45-69. doi: 10.1007/978-3-319-22822-8_4. Review.

PMID:
26424643
22.

Epstein-Barr Viruses (EBVs) Deficient in EBV-Encoded RNAs Have Higher Levels of Latent Membrane Protein 2 RNA Expression in Lymphoblastoid Cell Lines and Efficiently Establish Persistent Infections in Humanized Mice.

Gregorovic G, Boulden EA, Bosshard R, Elgueta Karstegl C, Skalsky R, Cullen BR, Gujer C, Rämer P, Münz C, Farrell PJ.

J Virol. 2015 Nov;89(22):11711-4. doi: 10.1128/JVI.01873-15. Epub 2015 Sep 2.

23.

Poxvirus Protein MC132 from Molluscum Contagiosum Virus Inhibits NF-B Activation by Targeting p65 for Degradation.

Brady G, Haas DA, Farrell PJ, Pichlmair A, Bowie AG.

J Virol. 2015 Aug;89(16):8406-15.

24.

Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection.

Palser AL, Grayson NE, White RE, Corton C, Correia S, Ba Abdullah MM, Watson SJ, Cotten M, Arrand JR, Murray PG, Allday MJ, Rickinson AB, Young LS, Farrell PJ, Kellam P.

J Virol. 2015 May;89(10):5222-37. doi: 10.1128/JVI.03614-14. Epub 2015 Mar 18.

25.

Dimerization of matrix protein is required for budding of respiratory syncytial virus.

Förster A, Maertens GN, Farrell PJ, Bajorek M.

J Virol. 2015 Apr;89(8):4624-35. doi: 10.1128/JVI.03500-14. Epub 2015 Feb 11.

26.

A single amino acid in EBNA-2 determines superior B lymphoblastoid cell line growth maintenance by Epstein-Barr virus type 1 EBNA-2.

Tzellos S, Correia PB, Karstegl CE, Cancian L, Cano-Flanagan J, McClellan MJ, West MJ, Farrell PJ.

J Virol. 2014 Aug;88(16):8743-53. doi: 10.1128/JVI.01000-14. Epub 2014 May 21.

27.

Statistical methods for active pharmacovigilance, with applications to diabetes drugs.

Zhuo L, Farrell PJ, McNair D, Krewski D.

J Biopharm Stat. 2014;24(4):856-73. doi: 10.1080/10543406.2014.901338.

PMID:
24697529
28.

Signal transducer and activator of transcription 3 limits Epstein-Barr virus lytic activation in B lymphocytes.

Hill ER, Koganti S, Zhi J, Megyola C, Freeman AF, Palendira U, Tangye SG, Farrell PJ, Bhaduri-McIntosh S.

J Virol. 2013 Nov;87(21):11438-46. doi: 10.1128/JVI.01762-13. Epub 2013 Aug 21.

29.

The -1195G allele increases the transcriptional activity of cyclooxygenase-2 gene (COX-2) in colon cancer cell lines.

Pereira C, Sousa H, Silva J, Brandão C, Elgueta-Karstegl C, Farrell PJ, Medeiros R, Dinis-Ribeiro M.

Mol Carcinog. 2014 Feb;53 Suppl 1:E92-5. doi: 10.1002/mc.22049. Epub 2013 Jun 18.

PMID:
23776069
30.

Novel function of the unique N-terminal region of RUNX1c in B cell growth regulation.

Brady G, Elgueta Karstegl C, Farrell PJ.

Nucleic Acids Res. 2013 Feb 1;41(3):1555-68. doi: 10.1093/nar/gks1273. Epub 2012 Dec 18.

31.

A simple technique to enhance the humoral immune response to intracellular protein antigens in genetic immunizations.

Farrell PJ, Kucknoor AS, Iatrou K, Gedamu L.

J Immunol Methods. 2013 Jan 31;387(1-2):308-11. doi: 10.1016/j.jim.2012.08.017. Epub 2012 Sep 3.

PMID:
22964556
32.

The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma.

Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D, Monteverde M, Merlano M, Papoudou-Bai A, Bai M, Schmid P, Stebbing J, Bower M, Dyer MJ, Karran LE, ElguetaKarstegl C, Farrell PJ, Thompson A, Briasoulis E, Crook T.

Br J Cancer. 2012 Oct 9;107(8):1423-32. doi: 10.1038/bjc.2012.380. Epub 2012 Sep 6.

33.

Genomic sequencing and comparative analysis of Epstein-Barr virus genome isolated from primary nasopharyngeal carcinoma biopsy.

Kwok H, Tong AH, Lin CH, Lok S, Farrell PJ, Kwong DL, Chiang AK.

PLoS One. 2012;7(5):e36939. doi: 10.1371/journal.pone.0036939. Epub 2012 May 10.

34.

Lytic Epstein-Barr virus infection in epithelial cells but not in B-lymphocytes is dependent on Blimp1.

Buettner M, Lang A, Tudor CS, Meyer B, Cruchley A, Barros MH, Farrell PJ, Jäck HM, Schuh W, Niedobitek G.

J Gen Virol. 2012 May;93(Pt 5):1059-64. doi: 10.1099/vir.0.038661-0. Epub 2012 Jan 25.

PMID:
22278826
35.

Epstein-barr virus sequence variation-biology and disease.

Tzellos S, Farrell PJ.

Pathogens. 2012 Nov 8;1(2):156-74. doi: 10.3390/pathogens1020156. Review.

36.

Association of innate immune activation with latent Epstein-Barr virus in active MS lesions.

Tzartos JS, Khan G, Vossenkamper A, Cruz-Sadaba M, Lonardi S, Sefia E, Meager A, Elia A, Middeldorp JM, Clemens M, Farrell PJ, Giovannoni G, Meier UC.

Neurology. 2012 Jan 3;78(1):15-23. doi: 10.1212/WNL.0b013e31823ed057. Epub 2011 Dec 7.

PMID:
22156987
37.

C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7.

Cancian L, Bosshard R, Lucchesi W, Karstegl CE, Farrell PJ.

PLoS Pathog. 2011 Jul;7(7):e1002164. doi: 10.1371/journal.ppat.1002164. Epub 2011 Jul 28.

38.

Cellular gene expression that correlates with EBER expression in Epstein-Barr Virus-infected lymphoblastoid cell lines.

Gregorovic G, Bosshard R, Karstegl CE, White RE, Pattle S, Chiang AK, Dittrich-Breiholz O, Kracht M, Russ R, Farrell PJ.

J Virol. 2011 Apr;85(7):3535-45. doi: 10.1128/JVI.02086-10. Epub 2011 Jan 19.

39.
40.

Outlier detection for a hierarchical Bayes model in a study of hospital variation in surgical procedures.

Farrell PJ, Groshen S, Macgibbon B, Tomberlin TJ.

Stat Methods Med Res. 2010 Dec;19(6):601-19. doi: 10.1177/0962280209344926. Epub 2010 Mar 11.

PMID:
20223782
41.

Regulation of the Epstein-Barr virus Zp promoter in B lymphocytes during reactivation from latency.

McDonald C, Karstegl CE, Kellam P, Farrell PJ.

J Gen Virol. 2010 Mar;91(Pt 3):622-9. doi: 10.1099/vir.0.017277-0. Epub 2009 Nov 18.

PMID:
19923262
42.

RUNX3-mediated repression of RUNX1 in B cells.

Brady G, Farrell PJ.

J Cell Physiol. 2009 Nov;221(2):283-7. doi: 10.1002/jcp.21880. Review.

PMID:
19603429
43.

Downregulation of RUNX1 by RUNX3 requires the RUNX3 VWRPY sequence and is essential for Epstein-Barr virus-driven B-cell proliferation.

Brady G, Whiteman HJ, Spender LC, Farrell PJ.

J Virol. 2009 Jul;83(13):6909-16. doi: 10.1128/JVI.00216-09. Epub 2009 Apr 29.

44.

Interaction of Epstein-Barr virus BZLF1 C-terminal tail structure and core zipper is required for DNA replication but not for promoter transactivation.

McDonald CM, Petosa C, Farrell PJ.

J Virol. 2009 Apr;83(7):3397-401. doi: 10.1128/JVI.02500-08. Epub 2009 Jan 14.

45.

Epstein-Barr virus BART gene expression.

Al-Mozaini M, Bodelon G, Karstegl CE, Jin B, Al-Ahdal M, Farrell PJ.

J Gen Virol. 2009 Feb;90(Pt 2):307-16. doi: 10.1099/vir.0.006551-0.

PMID:
19141439
46.

Epstein-Barr virus and Burkitt lymphoma.

Brady G, Macarthur GJ, Farrell PJ.

Postgrad Med J. 2008 Jul;84(993):372-7. doi: 10.1136/jcp.2007.047977. Review.

PMID:
18716017
47.

Differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2.

Lucchesi W, Brady G, Dittrich-Breiholz O, Kracht M, Russ R, Farrell PJ.

J Virol. 2008 Aug;82(15):7456-66. doi: 10.1128/JVI.00223-08. Epub 2008 May 14.

48.

Epstein-Barr virus and Burkitt lymphoma.

Brady G, MacArthur GJ, Farrell PJ.

J Clin Pathol. 2007 Dec;60(12):1397-402. Review.

49.

Role for HLA in susceptibility to infectious mononucleosis.

Farrell PJ.

J Clin Invest. 2007 Oct;117(10):2756-8.

50.

Testing for ordered group effects in binary and continuous outcomes.

Farrell PJ, Park CG.

Biom J. 2007 Aug;49(4):585-98.

PMID:
17634976

Supplemental Content

Loading ...
Support Center